Literature DB >> 26729456

Multi-Stage Mass Spectrometry Analysis of Sugar-Conjugated β-Turn Structures to be Used as Probes in Autoimmune Diseases.

Chiara Giangrande1,2, Nicolas Auberger3,4,5, Cédric Rentier6,7,8, Anna Maria Papini6,7,8, Jean-Maurice Mallet3,4,5, Solange Lavielle3,4,5, Joëlle Vinh9,10.   

Abstract

Synthetic sugar-modified peptides were identified as antigenic probes in the context of autoimmune diseases. The aim of this work is to provide a mechanistic study on the fragmentation of different glycosylated analogs of a synthetic antigenic probe able to detect antibodies in a subpopulation of multiple sclerosis patients. In particular the N-glucosylated type I' β-turn peptide structure called CSF114(Glc) was used as a model to find signature fragmentations exploring the potential of multi-stage mass spectrometry by MALDI-LTQ Orbitrap. Here we compare the fragmentation of the glucosylated form of the synthetic peptide CSF114(Glc), bearing a glucose moiety on an asparagine residue, with less or non- immunoreactive forms, bearing different sugar-modifications, such as CSF114(GlcNAc), modified with a residue of N-acetylglucosamine, and CSF114[Lys(7)(1-deoxyfructopyranosyl)], this last one modified with a 1-deoxyfructopyranosyl moiety on a lysine at position 7. The analysis was set up using a synthetic compound specifically deuterated on the C-1 to compare its fragmentation with the fragmentation of the undeuterated form, and thus ascertain with confidence the presence on an Asn(Glc) within a peptide sequence. At the end of the study, our analysis led to the identification of signature neutral losses inside the sugar moieties to characterize the different types of glycosylation/glycation. The interest of this study lies in the possibility of applyimg this approach to the discovery of biomarkers and in the diagnosis of autoimmune diseases. Graphical Abstract <!-- [INSERT GRAPHICAL ABSTRACT TEXT HERE] -->.

Entities:  

Keywords:  Autoimmune diseases; CID fragmentation; Glycosylation; Mass spectrometry; β-Turn structures

Mesh:

Substances:

Year:  2016        PMID: 26729456     DOI: 10.1007/s13361-015-1321-9

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


  35 in total

1.  Designed glycopeptides with different beta-turn types as synthetic probes for the detection of autoantibodies as biomarkers of multiple sclerosis.

Authors:  Alfonso Carotenuto; Maria Claudia Alcaro; Maria Rosaria Saviello; Elisa Peroni; Francesca Nuti; Anna Maria Papini; Ettore Novellino; Paolo Rovero
Journal:  J Med Chem       Date:  2008-08-20       Impact factor: 7.446

Review 2.  The use of post-translationally modified peptides for detection of biomarkers of immune-mediated diseases.

Authors:  Anna Maria Papini
Journal:  J Pept Sci       Date:  2009-10       Impact factor: 1.905

3.  Comparison of Glycopeptide Fragmentation by Collision Induced Dissociation and Ultraviolet Photodissociation.

Authors:  Byoung Joon Ko; Jennifer S Brodbelt
Journal:  Int J Mass Spectrom       Date:  2015-02-01       Impact factor: 1.986

4.  Antibody recognition in multiple sclerosis and Rett syndrome using a collection of linear and cyclic N-glucosylated antigenic probes.

Authors:  Feliciana Real Fernández; Margherita Di Pisa; Giada Rossi; Nicolas Auberger; Olivier Lequin; Maud Larregola; Amina Benchohra; Christelle Mansuy; Gerard Chassaing; Francesco Lolli; Joussef Hayek; Solange Lavielle; Paolo Rovero; Jean-Maurice Mallet; Anna Maria Papini
Journal:  Biopolymers       Date:  2015-09       Impact factor: 2.505

Review 5.  Chemical approaches to glycobiology.

Authors:  Laura L Kiessling; Rebecca A Splain
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

6.  The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis.

Authors:  Francesco Lolli; Benedetta Mazzanti; Marta Pazzagli; Elisa Peroni; Maria Claudia Alcaro; Giuseppina Sabatino; Roberta Lanzillo; Vincenzo Brescia Morra; Lucio Santoro; Claudio Gasperini; Stefania Galgani; Mario Milco D'Elios; Valentina Zipoli; Stefano Sotgiu; Maura Pugliatti; Paolo Rovero; Mario Chelli; Anna Maria Papini
Journal:  J Neuroimmunol       Date:  2005-10       Impact factor: 3.478

7.  Screening and sequencing of glycated proteins by neutral loss scan LC/MS/MS method.

Authors:  Himanshu S Gadgil; Pavel V Bondarenko; Michael J Treuheit; Da Ren
Journal:  Anal Chem       Date:  2007-06-16       Impact factor: 6.986

8.  The Haemophilus influenzae HMW1 adhesin is glycosylated in a process that requires HMW1C and phosphoglucomutase, an enzyme involved in lipooligosaccharide biosynthesis.

Authors:  Susan Grass; Amy Z Buscher; W Edward Swords; Michael A Apicella; Stephen J Barenkamp; Neil Ozchlewski; Joseph W St Geme
Journal:  Mol Microbiol       Date:  2003-05       Impact factor: 3.501

9.  A mechanistic study on the fragmentation of peptide-derived Amadori products.

Authors:  Piotr Stefanowicz; Katarzyna Kapczynska; Mariusz Jaremko; Łukasz Jaremko; Zbigniew Szewczuk
Journal:  J Mass Spectrom       Date:  2009-10       Impact factor: 1.982

10.  Building blocks for the synthesis of post-translationally modified glycated peptides and proteins.

Authors:  Stefano Carganico; Paolo Rovero; Jose A Halperin; Anna Maria Papini; Michael Chorev
Journal:  J Pept Sci       Date:  2009-02       Impact factor: 2.408

View more
  2 in total

1.  Electron-Transfer/Higher-Energy Collision Dissociation (EThcD)-Enabled Intact Glycopeptide/Glycoproteome Characterization.

Authors:  Qing Yu; Bowen Wang; Zhengwei Chen; Go Urabe; Matthew S Glover; Xudong Shi; Lian-Wang Guo; K Craig Kent; Lingjun Li
Journal:  J Am Soc Mass Spectrom       Date:  2017-07-10       Impact factor: 3.109

2.  Glyco-Decipher enables glycan database-independent peptide matching and in-depth characterization of site-specific N-glycosylation.

Authors:  Zheng Fang; Hongqiang Qin; Jiawei Mao; Zhongyu Wang; Na Zhang; Yan Wang; Luyao Liu; Yongzhan Nie; Mingming Dong; Mingliang Ye
Journal:  Nat Commun       Date:  2022-04-07       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.